Lv21
140 积分 2025-12-15 加入
Toxicological Aspects of PROTACs
1个月前
已完结
In vivo toxicology of excipients commonly employed in drug discovery in rats
1个月前
已完结
Induced proximity-based therapeutic modalities
2个月前
已完结
Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti-Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties
2个月前
已完结
Compilation and use of genetic toxicity historical control data
4个月前
已完结
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
5个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
5个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
5个月前
已完结
Toxicologic Pathology Forum*: Opinion on Qualitative Severity Descriptors to Express Magnitude of Changes in Clinical Pathology Endpoints in Nonclinical Toxicity Studies
9个月前
已完结
皖公网安备34019202002308
